As reported by BBC news, new coronavirus vaccine has been shown to be 89.3% effective in large-scale UK trials
The Novavax jab is the first to show in trials that it is effective against the new virus variant found in the UK, the BBC’s medical editor Fergus Walsh said. The PM welcomed the “good news” and said the UK’s medicines regulator would now assess the vaccine.
The UK has secured 60m doses of the jab, which will be made in Stockton-on-Tees in north-east England. The doses are expected to be delivered in the second half of this year, if approved for use by the Medicines and Healthcare Products Regulatory Agency (MHRA), the government said.
The UK has so far approved three coronavirus vaccines for emergency use – one from Oxford University and AstraZeneca, another by Pfizer and BioNTech, and a third from drug firm Moderna. The Novavax jab, which is given in two doses, was shown to be 89.3% effective at preventing COVID-19 in participants in its Phase 3 clinical trial in the UK.
The Phase 3 trials – the final stage before a vaccine is looked at by a regulator – enrolled more than 15,000 people aged between 18-84, of whom 27% were older than 65, US firm Novavax said.
In the South African part of the trial, where most of the cases were the South African variant of the virus, the vaccine was 60% effective among those without HIV.
Stan Erck, chief executive of Novavax, said the results from the UK trial were “spectacular” and “as good as we could have hoped”, while the efficacy in South Africa was “above people’s expectations”.
He told the BBC the manufacturing plant in Stockton-on-Tees should be up and running by March or April, with the company hoping to get approval for the vaccine from the MHRA around the same time.
Minister Lucy Frazer told BBC Breakfast the government could not put an exact timeframe on when the Novavax jab might be approved as the regulation process is “out of our control”.
But she said the NHS would be “ready to distribute [the jab] into people’s arms” as soon as supplies are available.
Health secretary Matt Hancock said the new vaccine would be “another weapon in our arsenal to beat this awful virus”, if approved.
Thanking researches and volunteers who took part in the trials, he added: “I’m proud the UK is at the forefront of another medical breakthrough.”
Prof Paul Heath, chief investigator of the UK Novavax trial, said the findings of the clinical trials were “enormously exciting findings”, particularly because of the jab’s efficacy against the UK variant.
Peter Openshaw, professor of experimental medicine at Imperial College London, said the findings that the vaccine gave high levels of protection in the UK part of the trial were “excellent” but that the lower level of protection seen in South Africa was “a concern”.